Q-omics provides the consensus-scored GAPDHP55 profile across patient tissues and cancer cell-line models. GAPDHP55 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GAPDHP55 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, GAPDHP55 RNA expression shows 8,418 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight MESO, KIRC, and UCEC as cancer lineages where GAPDHP55 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP55 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP55 survival associations across molecular data types. GAPDHP55 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP55 RNA expression–survival associations across cancer types. High GAPDHP55 expression shows unfavorable associations in MESO, KIRP, THYM, STAD, BRCA and KICH. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GAPDHP55 RNA expression.
This table summarizes GAPDHP55 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP55. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP55 shows higher tumor expression in KIRC, LUSC, HNSC, LUAD, KIRP and LIHC. The KIRC box plot shows higher GAPDHP55 RNA expression in tumor versus normal tissue (log2 FC = +0.098, t-test p < 0.001).
This table shows molecular features associated with GAPDHP55 in patient tissues and cancer cell lines. In patient samples, GAPDHP55 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
